NEW White Paper
Hot ‘N’ Cold: Decoding Glioblastoma’s Complex Immune Landscape
This white paper presents a strategic platform for leveraging patient-derived xenografts, humanized models, and predictive technologies to identify, optimize, and translate promising immunotherapeutic strategies.
An Integrated Preclinical Platform for GBM Immunotherapy Development
By integrating tumor mutational burden analysis, HLA profiling, and multi-modal endpoint assessment, researchers can design rational combination therapies that address GBM’s complex immune landscape with unprecedented precision. Download our white paper to learn how to:
- Examine the immune architecture of glioblastoma and its impact on immunotherapy response
- Understand dominant GBM immune-evasion mechanisms that drive resistance in preclinical studies
- Evaluate patient-derived and orthotopic GBM models that more accurately recapitulate tumor–immune interactions
- Leverage immune biomarkers and molecular profiling to guide model selection and study design
- Apply integrated preclinical approaches and AI-driven analytics to de-risk immuno-oncology development
Download White Paper
Proven in Preclinical GBM Research
Our collection of 57 low-passage brain cancer models—including 51 GBM specimens—represents the most comprehensive bank of clinically relevant models available to researchers today.
Your Translational Partner
Certis Oncology Solutions is a life science technology company committed to realizing the promise of precision oncology. Our product is Certis Oncology Intelligence® — highly predictive therapeutic response data derived from advanced biological models of cancer and enhanced with AI-driven bioinformatics. Our functional platform informs individual treatment and drug development decisions. Certis incorporates both 3D cell-based assays and in silico models to accelerate the development of new cancer therapies and reduce the number of animal models.